ArticleHealthcare (Basel, Switzerland)2020
Factors Associated with Disparities in Appropriate Statin Therapy in an Outpatient Inner City Population.
Article in Healthcare (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Statin Use and Primary Open-Angle Glaucoma Severity in Patients of African Ancestry.Research square · 2026Article
- Assessing Prescribing Patterns of Nonstatins as Add-on Therapy for Secondary Prevention in a Federally Qualified Health Center.Pharmacy (Basel, Switzerland) · 2025Article
- Use of Lipid-Lowering Treatment in Primary Prevention in Spain (Lipidspain).Journal of clinical medicine · 2025Article
- Obesity modulates NK cell activity via LDL and DUSP1 signaling for populations with adverse social determinants.JCI insight · 2024Article
- Reinstating LDL-C Measurement as a Quality Metric: This Is the Way.JACC. Advances · 2024Article
- Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models.Reviews in cardiovascular medicine · 2023Review
- Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex.JAMA network open · 2023Article
- The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology.American journal of preventive cardiology · 2023Review
- Statin Eligibility according to 2013 ACC/AHA and USPSTF Guidelines among Jordanian Patients with Acute Myocardial Infarction: The Impact of Gender.Cardiovascular therapeutics · 2023Observational
- Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease.Clinical cardiology · 2023Review
- Racial, ethnic, and language differences in screening measures for statin therapy following a major guideline change.Preventive medicine · 2022Article
- Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations: a quality improvement intervention centred on a novel interactive tool.BMJ open quality · 2022Article
- Black lives matter … in the cath lab, too! A proposal for the interventional cardiology community to counteract bias and racism.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2022Article
- Gaps and Disparities in Primary Prevention Statin Prescription During Outpatient Care.The American journal of cardiology · 2021Article
- Inequities in atherosclerotic cardiovascular disease prevention.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-lowering therapies are essential for the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). The aim of this study is to identify discrepancies between cholesterol management guidelines and current practice with a focus on statin treatment in an underserved population based in a large single urban medical center. Among 1042 reviewed records, we identified 464 statin-eligible patients. Age was 61.0 ± 10.4 years and 53.9% were female. Most patients were black (47.2%), followed by Hispanic (45.7%) and white (5.0%). In total, 82.1% of patients were prescribed a statin. An appropriate statin was not prescribed in 32.4% of statin-eligible patients who qualified based only on a 10-year ASCVD risk of ≥7.5%. After adjustment for gender and health insurance status, appropriate statin treatment was independently associated with age >55 years (OR = 4.59 (95% CI 1.09-16.66),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.